Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Jagsonpal Pharmaceuticals has informed that the Nomination and Remuneration Committee has issued and allotted 22,150 Equity Shares of Rs. 2/- each under JPL ESOP 2022, to the eligible employee of the Company, upon exercise of vested options. These shares shall rank with the existing equity shares of the Company, in all respects. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,27,29,810 (constituting of 6,63,64,905 equity shares of Rs. 2/- each) to Rs. 13,27,74,112 (constituting of 6,63,87,056 equity shares of Rs. 2/- each). Details under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, is attached.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: